Pharmacokinetics in IBD: Ready for Prime Time?

Title:Pharmacokinetics in IBD: Ready for Prime Time?

Volume: 15 Issue: 11

Author(s): Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul

Affiliation:

Keywords: Antibodies to anti TNF, anti TNF treatment, Crohn’s disease, optimisation, trough levels of anti TNF, ulcerative colitis.

Abstract: This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].

Cite this article as:

Roblin Xavier, Rinaudo Melanie, Sparrow Peter Miles, Moreau Amelie, Phelip Marc Jean, Genin Christian, Lamarque Dominique and Paul Stephane, Pharmacokinetics in IBD: Ready for Prime Time?, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140829153509